The role of metalloproteinases and their inhibitors in pancreatic cancer;Rola metaloproteinaz i ich inhibitorów w raku trzustki

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 62, Issue , 2008, Pages 141-147

  Łukaszewicz, Marta ^a   Mroczko, Barbara ^a   Szmitkowski, Maciej ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Metalloproteinases; Pancreatic cancer

Indexed keywords

MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR MARKER;

ADENOCARCINOMA; CANCER INVASION; CANCER STAGING; DISEASE COURSE; ENZYMOLOGY; EUROPE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); NORTH AMERICA; PANCREAS TUMOR; PATHOLOGY; REVIEW;

ADENOCARCINOMA; DISEASE PROGRESSION; EUROPE; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASES; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; NORTH AMERICA; PANCREATIC NEOPLASMS; TISSUE INHIBITOR OF METALLOPROTEINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 43249107538     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Blavier L., Henriet P., Imren S., Declerck Y.A.: Tissue inhibitors of matrix metalloproteinases in cancer. Ann. NY Acad. Sci., 1999; 878: 108-119
2. Bloomston M., Shafii A., Zervos E.E., Rosemurgy A.S.: TIMP-1 overexpression in pancreatic cancer attenuates tumor growth, decreases implantation and metastasis, and inhibits angiogenesis. J. Surg. Res., 2002; 102: 39-44
3. Egeblad M., Werb Z.: New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer, 2002; 2: 161-174
4. Ellenrieder V., Alber B., Lacher U., Hendler S.F., Menke A., Boeck W., Wagner M., Wilda M., Friess H., Buchler M., Adler G., Gress T.M.: Role of MT-MMPs and MMP-2 in pancreatic cancer progression. Int. J. Cancer, 2000; 85: 14-20
5. Evans J.D., Stark A., Johnson C.D., Daniel F., Carmichael J., Buckels J., Imrie C.W., Brown P., Neoptolemos J.P.: A phase II trial of marimastat in advanced pancreatic cancer. Br. J. Cancer, 2001; 85: 1865-1870
6. Gabryelewicz A.: Choroby nowotworowe przewodu pokarmowego. Gastroenterologia w praktyce, red.: A. Gabryelewicz, PZWL, Warszawa 2002, 251-297
7. Guo Y., Li X.N., Li S.Y., Zong Z.H., Wang X.R., Yu B.Z.: Zymographic analysis of MMPs in human cerebrospinal fluid with brain tumor. Zhongguo Yike Daxue Xuebao, 2000; 29: 10-12
8. Gurevich L.E.: Role of matrix metalloproteinases 2 and 9 in determination of invasive potential of pancreatic tumors. Bull. Exp. Biol. Med., 2003; 136: 494-498
9. Haq M., Shaeii A.E., Zervos E.E., Rosemurgy A.S.: In vitro and in vivo matrix metalloproteinase production by pancreatic cancer cells and by distant organs. Int. J. Surg. Investig., 2000; 1: 459-465
10. Harvey S.R., Hurd T.C., Markus G., Martinick M.I., Penetrante R.M., Tan D., Venkataraman P., DeSouza N., Sait S.N., Driscoll D.L., Gibbs J.F.: Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer. Clin. Cancer Res., 2003; 9: 4935-4943
11. Iki K., Takeo T., Kubozoe T., Aoki S., Hayashi J., Tsunoda T.: Detection of serum MMPs in tumor-bearing hamsters. J. Hepatobiliary Pancreat. Surg., 2002; 9: 478-484
12. Ito T., Ito M., Shiozawa J., Naito S., Kanematsu T., Sekine I.: Expression of the MMP-1 in human pancreatic carcinoma: relationship with prognostic factor. Mod. Pathol., 1999; 12: 669-674
13. Jinga D.C., Blidaru A., Condrea I., Ardeleanu C., Dragomir C., Szegli G., Stefanescu M., Matache C.: MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors. J. Cell. Mol. Med., 2006; 10: 499-510
14. Jones L.E., Humphreys M.J., Campbell F., Neoptolemos J.P., Boyd M.T.: Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival. Clin. Cancer Res., 2004; 10: 2832-2845
15. Kołomecki K.: Hamowanie funkcji metaloproteinaz-mozliwos̈ci zastosowania klinicznego. Onkol. Pol., 2000; 3: 163-167
16. Kotulska-Wolwender K., Larysz-Brysz M., Fus Z., Korczyńska I., Górka D., Lewin-Kowalik J.: Metaloproteinazy macierzy pozakomórkowej-perspektywy ich wykorzystania w medycynie. Wiad. Lek., 2002; 55: 463-471
17. Lafleur M.A., Handsley M.M., Edwards D.R.: Metalloproteinases and their inhibitors in angiogenesis. Expert. Rev. Mol. Med., 2003; 5: 1-39
18. Lambert E., Dasse E., Haye B., Petitfrere E.: TIMPs as multifacial proteins. Crit. Rev. Oncol. Hematol., 2004; 49: 187-198
19. Leppert D., Lindberg R.L., Kappos L., Leib S.L.: Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res. Brain Res. Rev., 2001; 36: 249-257
20. Li Y.Y., McTiernan C.F., Feldman A.M.: Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc. Res., 2000; 46: 214-224
21. Lowenfels A.B., Maisonneuve P.: Epidemiology and risk factors for pancreatic cancer. Best Pract. Res. Clin. Gastroenterol., 2006; 20: 197-209
22. Moilanen M., Pirila E., Grenman R., Sorsa T., Salo T.: Expression and regulation of collagenase-2 (MMP-8) in head and neck squamous cell carcinomas. J. Pathol., 2002; 197: 72-81
23. Murray G.I., Duncan M.E, Arbuckle E., Melvin W.T., Fothergill J.E.: Matrix metalloproteinases and their inhibitors in gastric cancer. Gut, 1998; 43: 791-797
24. Murray G.I., Duncan M.E, O'Neil P., McKay J.A., Melvin W.T., Fothergill J.E.: Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J. Pathol., 1998; 185: 256-261
25. Murray G.I., Duncan M.E., O'Neil P., Melvin W.T., Fothergill J.E.: Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat. Med., 1996; 2: 461-462
26. Nabeshima K., Inoue T., Shimao Y., Sameshima T.: Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol. Int., 2002; 52: 255-264
27. Nagakawa Y., Aoki T., Kasuya K., Tsuchida A., Koyanagi Y.: Histologic features of venous invasion, expression of vascular endothelial growth factor and matrix metalloproteinase-2 and matrix metalloproteinase-9, and the relation with liver metastasis in pancreatic cancer. Pancreas, 2002; 24: 169-178
28. Nagase H., Woessner J.F.Jr.: Matrix metalloproteinases. J. Biol. Chem., 1999; 274: 21491-21494
29. Nikkola J., Vihinen P., Vuoristo M.S., Kellokumpu-Lehtinen P., Kahari V.M., Pyrhonen S.: High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin. Cancer Res., 2005; 11: 5158-5166
30. Ottaviano A.J., Sun L., Ananthanarayanan V., Munshi H.G.: Extracellular matrix-mediated membrane-type 1 matrix metalloproteinase expression in pancreatic ductal cells is regulated by transforming growth factor-b1. Cancer Res., 2006; 66: 7032-7040
31. Palosaari H. Matrix metalloproteinases (MMPs) and their specific tissue inhibitors (TIMPs) in mature human odontoblasts and pulp tissue. The regulation of expression of fibrillar collagens, MMPs and TIMPs by growth factors, transforming growth factor-b1 (TGF-b1) and bone morhogrnetic protein-2 (BMP-2). University of Oulu, Oulu Finland 2003
32. Patten L.C., Berger D.H.: Role of proteases in pancreatic carcinoma. World J. Surg., 2005; 29: 258-263
33. Stadlmann S., Pollheimer J., Moser P.L., Raggi A., Amberger A., Margreiter R., Offner F.A., Mikuz G., Dirnhofer S., Moch H.: Cytokineregulated expression of collagenase-2 (MMP-8) is involved in the progression of ovarian cancer. Eur. J. Cancer, 2003; 39: 2499-2505
34. ͆liwowska I., Kopczyński Z.: Metaloproteinazy macierzy zewnątrzkomórkowej-charakterystyka biochemiczna i kliniczna wartos̈ć oznaczania u chorych na raka piersi. Współ. Onkol., 2005; 8: 327-335
35. Torii A., Kodera Y., Uesaka K., Hirai T., Yasui K., Morimoto T., Yamamura Y., Kato T., Hayakawa T., Fujimoto N., Kito T.: Plasma concentration of matrix metalloproteinase 9 in gastric cancer. Br. J. Surg., 1997; 84: 133-136
36. Tu F.F., Goldenberg R.L., Tamura T., Drews M., Zucker S.J., Voss H.F.: Prenatal plasma matrix metalloproteinase-9 levels to predict spontaneous preterm birth. Obstet. Gynecol., 1998; 92: 446-449
37. Waas E.T., Lomme R.M., DeGroot J., Wobbes T., Hendriks T.: Tissue levels of active matrix metalloproteinase-2 and-9 in colorectal cancer. Br. J. Cancer, 2002; 86: 1876-1883
38. Wojtowicz-Praga S.M., Dickson R.B., Hawkins M.J.: Matrix metalloproteinase inhibitors. Invest. New Drugs, 1997; 15: 61-75
39. Yamamoto H., Itoh F., Iku S., Adachi Y., Fukushima H., Sasaki S., Mukaiya M., Hirata K., Imai K.: Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression. J. Clin. Oncol., 2001; 19: 1118-1127
40. Yang X., Staren E.D., Howard J.M., Iwamura T., Bartsch J.E., Appert H.E.: Invasiveness and MMP expression in pancreatic carcinoma. J. Surg. Res., 2001; 98: 33-39
41. Ylisirnio S., Hoyhtya M., Turpeenniemi-Hujanen T.: Serum matrix metalloproteinases-2,-9 and tissue inhibitors of metalloproteinases-1,-2 in lung cancer-TIMP-1 as prognostic marker. Anticancer Res., 2000; 20: 1311-1316
42. Yokoyama M., Ochi K., Ichimura M., Mizushima T., Shinji T., Koide N., Tsurumi T., Hasuoka H., Harada M.: Matrix metalloproteinase-2 in pancreatic juice for diagnosis of pancreatic cancer. Pancreas, 2002; 24: 344-347
43. Yong V.W., Power C., Forsyth P., Edwards D.R.: Metalloproteinases in biology and pathology of the nervous system. Nat. Rev. Neurosci., 2001; 2: 502-511
44. Zhang Q., Chen L.B., Zang J., Chu X.Y.: Detection of matrix metalloproteinases in urine of breast cancer patients with zymography. Nanjing Daxue Xuebao, 2002; 38: 192-195
45. Zucker S., Hymowitz M., Conner C., Zarrabi H.M., Hurewitz A.N., Matrisian L., Boyd D., Nicolson G., Montana S.: Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann. NY Acad. Sci., 1999; 878: 212-227